Divalproex Sodium Market Growth Analysis | 2023-2028

Market Insights

The divalproex sodium market was estimated at USD 2.37 billion in 2022 and is likely to grow at a CAGR of 6.04% during 2023-2028 to reach USD 3.38 billion in 2028.

Wish to get a free scope on this study? Click here.

What is divalproex sodium?

Divalproex sodium is a Food and Drug Administrator (FDA) approved anti-epileptic drug that is used to treat migraine headaches, certain types of seizures, and manic episodes of bipolar disorders. It is widely known for its anti-convulsant properties for the treatment of epilepsy. It is also used in various combinational therapies.

COVID-19 Impact

The COVID-19 outbreak has moderately affected the divalproex sodium industry. This is mainly attributed to the shift of medical care towards coronavirus-infected patients. However, rising cases of bipolar disorder due to stress during the pandemic is expected to surge product demand amid the pandemic.

Key Players

Key players operating in the global market are-

• AbbVie (The U.S),
• Mylan, Zydus Pharms USA,
• Aurobindo Pharma (India),
• Dr Reddys Labs (India),
• LUPIN (India),
• Orchid (India),
• Sun Pharm (India), and
• Teva (Israel).

Market Dynamics

Growing prevalence of bipolar disorders across the globe is augmenting the market growth.

• Also, the increasing patient pool across the globe affected migraine and epilepsy headaches, thus propelling the product demand.
• In addition, rising awareness of diseases and several government initiatives to prevent head migraine is likely to boost the industry growth during the review period.

Want to have a closer look at this market report? Click Here.

Segments Analysis

By Form Type

Based on form, the divalproex sodium market is classified into Capsules, Tablets, and Syrup.

• The tablet segment is expected to hold the largest share in this market segment during the forecast period.
• Divalproex sodium oral tablet, also known as Depakote ER and Depakote, is used in various combinational therapies for treating bipolar disorders, complex partial seizures, and migraine headaches.
• The recommended initial dosage is 750 mg daily, with complex partial seizures starting at 10 to 15 mg/kg/day. Extended-release tablets, valproate, are used for acute manic or mixed episodes associated with bipolar disorder.
• Tablets are more shelf-stable and have a longer shelf life than capsules, making them ideal for treatments requiring a greater dosage.

By Application Type

Based on application, the divalproex sodium market is classified into epilepsy, manic depressive illness, and others.

• The epilepsy segment held a significant share in 2022 and is projected to grow at the highest CAGR during the assessment period.
• This is mainly attributed to the rising prevalence of epilepsy among kids and adults.
• Also, as per WHO 2018 facts, around 50 million people were globally affected with epilepsy and around 80% of the people with epilepsy live in low- and middle-income countries which further bolsters the segment growth.

Regional Insights

By region, the North American market accounted for the largest share in 2022 and is expected to grow at a substantial CAGR in the following years.

• This is mainly ascribed to rising government initiatives and increasing research & development for the introduction of new products are expected to aid in the growth of the divalproex sodium market in the region.
• In addition, strong healthcare infrastructure, increasing healthcare expenditure, and supportive reimbursement policies, further proliferates the regional market growth.

Know the high-growth countries in this report. Click here

Critical Questions Answered in the Report

• What are the key trends in the global market?
• How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
• What is the impact of COVID-19 on the global market?
• What are the key strategies adopted by the major vendors to lead in the market?
• What is the market share of the top vendors?

Market Segmentation

This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

The divalproex sodium market is segmented into the following categories.

By Form Type

• Capsule
• Tablet
• Syrup

By Distribution Channel Type

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Installation Type

• Epilepsy
• Manic Depressive Illness
• Others

By Region

• North America (Country Analysis: The USA, Canada, and Mexico)
• Europe (Country Analysis: Germany, France, The UK, Italy, Russia, and The Rest of Europe)
• Asia-Pacific (Country Analysis: Japan, China, India, South Korea, and The Rest of Asia-Pacific)
• Rest of the World (Country Analysis: Brazil, Saudi Arabia, and Others)

Click Here, to learn the market segmentation details.

Target Audience

Here is the list of the group of customers that the Divalproex Sodium Market hopes to have the greatest opportunity to convert-

• Divalproex sodium vendors
• Divalproex sodium retailers
• Epilepsy organizations
• Psychiatrists

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools.

More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Report Customization Option

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to 3 players)
• SWOT analysis of key players (up to 3 players)

Market Segmentation

• Current market segmentation of any one of the form types by application type.

Competitive Benchmarking

• Benchmarking of key players on the following parameters: product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.